Article Details
Retrieved on: 2021-05-11 08:30:29
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
CT-P39, a biosimilar of omalizumab (Xolair) is a humanised anti-immunoglobulin E monoclonal antibody. The drug is being developed by Celltrion, ...
Article found on: ksusentinel.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here